×
About 8,368 results

ALLMedicine™ Portal Hypertension Center

Research & Reviews  2,774 results

Investigational drugs in early clinical development for portal hypertension.
https://doi.org/10.1080/13543784.2022.2095259
Expert Opinion on Investigational Drugs; Rodrigues SG, Mendoza YP et. al.

Jun 28th, 2022 - Advanced chronic liver disease is considered a reversible condition after removal of the primary aetiological factor. This has led to a paradigm shift in which portal hypertension (PH) is a reversible complication of cirrhosis. The pharmacologic m...

The portal vein in patients with cirrhosis is not an excessively inflammatory or hyperc...
https://doi.org/10.1111/jth.15797
Journal of Thrombosis and Haemostasis : JTH; Driever EG, Magaz M et. al.

Jun 25th, 2022 - A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of haemostasis in the portal...

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT04365868

Jun 24th, 2022 - This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic s...

see more →

Guidelines  7 results

NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PORTAL HYPERTENSION.
https://doi.org/10.1016/j.clinre.2021.101767
Clinics and Research in Hepatology and Gastroenterology; Thabut D, Weil D et. al.

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

Non-invasive diagnosis and follow-up of primary biliary cholangitis.
https://doi.org/10.1016/j.clinre.2021.101770
Clinics and Research in Hepatology and Gastroenterology; Corpechot C, Heurgue A et. al.

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension.
https://doi.org/10.1016/j.jacr.2021.02.013
Journal of the American College of Radiology : JACR; , Pinchot JW et. al.

May 8th, 2021 - Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pr...

AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review.
https://doi.org/10.1016/j.cgh.2021.01.027
Clinical Gastroenterology and Hepatology : the Official C... Henry Z, Patel K et. al.

Jan 26th, 2021 - Management of bleeding gastric varices (GV) presents a unique challenge for patients with portal hypertension. Despite over thirty years of diagnostic and treatment advances standardized practices for bleeding GV are lacking and unsupported by ade...

Transjugular intrahepatic portosystemic stent-shunt in the management of portal hyperte...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306985
Gut Tripathi D, Stanley AJ et. al.

Mar 3rd, 2020 - These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  389 results

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT04365868

Jun 24th, 2022 - This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic s...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02400216

Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...

Sexual Dysfunction in Cirrhosis
https://clinicaltrials.gov/ct2/show/NCT05428267

Jun 23rd, 2022 - PREVALENCE OF ERECTILE DYSFUNCTION IN PATIENTS WITH CIRRHOSIS BEFORE AND AFTER LIVER TRANSPLANTATION. EFFECTIVENESS OF PHOSPHODIESTERASE-5 INHIBITORS. Research objectives The aims of investigators study are: (1) to compare the prevalence of erecti...

see more →

News  167 results

PI-based DAAs appear safe in decompensated patients
https://www.mdedge.com/internalmedicine/article/254814/hepatology/pi-based-daas-appear-safe-decompensated-patients
Jim Kling

May 22nd, 2022 - SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompen.

TIPS plus sequential systemic therapy shows promise in advanced HCC with tumor thrombus-related SPH
https://www.mdedge.com/gihepnews/article/254679/hepatocellular-carcinoma/tips-plus-sequential-systemic-therapy-shows

May 17th, 2022 - Key clinical point: Transjugular intrahepatic portosystemic shunt (TIPS) plus sequential systemic therapy is safe and feasible for treating portal vein tumor thrombus (PVTT)-related symptomatic portal hypertension (SPH) in advanced hepatocellular.

SPSS Diameter Predicts Liver Function After BRTO
https://www.medscape.com/viewarticle/970596

Mar 21st, 2022 - Patients with cirrhosis and larger spontaneous shunt diameters showed a significantly greater increase in hepatic venous pressure gradient (HVPG) following balloon-occluded retrograde transvenous obliteration compared to patients with smaller shun...

Shunt diameter predicts liver function after obliteration procedure
https://www.mdedge.com/internalmedicine/article/252903/gastroenterology/shunt-diameter-predicts-liver-function-after
Heidi Splete

Mar 18th, 2022 - Patients with cirrhosis and larger spontaneous shunt diameters showed a significantly greater increase in hepatic venous pressure gradient (HVPG) following balloon-occluded retrograde transvenous obliteration compared to patients with smaller shun.

MHRA Highlights Liver Injury Risk with Combination Therapy for Cystic Fibrosis
https://www.medscape.com/viewarticle/968905

Feb 22nd, 2022 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update highlighting the risk of serious liver injury following treatment with a combination therapy for cystic fibrosis. Ivacaftor/elexacaftor/tezacaftor (Kaft...

see more →

Patient Education  8 results see all →